The global preimplantation genetic diagnosis market size has the potential to grow by USD 131.99 million during 2019-2023, and the market’s growth momentum will accelerate throughout the forecast period because of the steady increase in the year-over-year growth.
This report provides a detailed analysis of the market by geography (Asia, Europe, North America, and ROW) and end-users (fertility clinics and maternity centers, hospitals and diagnostic laboratories, and research institutes). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Genea Ltd., Igenomix Sl, Illumina Inc., Invitae Corp., Laboratory Corp. of America Holdings, Natera Inc., Oxford Gene Technology Group, PerkinElmer Inc., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.
Market Overview
Browse TOC and LoE with selected illustrations and example pages of preimplantation genetic diagnosis market
Market Competitive Analysis
The market is concentrated, and the degree of concentration will decrease during the forecast period. The key players in the market are focusing on various growth strategies such as mergers and acquisitions, divestitures, joint ventures, and partnerships to expand the geographical reach and gain major market shares and revenue. PerkinElmer Inc., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc. are a few of the major market participants. Although the accelerating growth momentum will offer immense growth opportunities, concerns about safety and privacy of genetic data will challenge the growth of market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market positions, this preimplantation genetic diagnosis market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this preimplantation genetic diagnosis market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading preimplantation genetic diagnosis companies, including:
- Genea Ltd.
- Igenomix Sl
- Illumina Inc.
- Invitae Corp.
- Laboratory Corp. of America Holdings
- Natera Inc.
- Oxford Gene Technology Group
- PerkinElmer Inc.
- Quest Diagnostics Inc.
- Thermo Fisher Scientific Inc.
Preimplantation Genetic Diagnosis Market: Segmentation by Region
For more insights on the preimplantation genetic diagnosis market share of various regions Request for a FREE sample now!
North America was the largest market for preimplantation genetic diagnosis in 2018, and the region will continue to offer maximum growth opportunities to market vendors during the forecast period. The increasing use of PGD for sex selection and early diagnosis of heritable disorders and diseases will contribute to the preimplantation genetic diagnosis market growth in the region.
Over 35% of the market’s growth will originate from North America during the forecast period. The US, Mexico, and Canada are the key markets of preimplantation genetic diagnosis in North America. Market growth in this region will be faster than the growth of the market in Europe and ROW.
Preimplantation Genetic Diagnosis Market: Segmentation by End-Users
Request for a FREE sample and Get more information on the market contribution of various end-users
A significant number of IVF cycles are performed in fertility clinics and maternity centers because of the promising success rates of fertility treatments. PGD is an integral part of IVF and is highly recommended to patients who have a history of genetic disorders, and fertility clinics and maternity centers are among the prime consumers of PGD products. Therefore, the demand for PGD testing to increase the chances of successful IVF pregnancies in couples with prior unexplainable IVF failures has driven the global PGD market growth by the fertility clinics and maternity centers segment.
Moreover, market growth by the fertility clinics and maternity centers segment will be faster than the development of the market by the hospitals and diagnostic laboratories and research institutes segments. This report provides an accurate prediction of the contribution of all the segments to the growth of the preimplantation genetic diagnosis market size.
Preimplantation Genetic Diagnosis Market: Key Drivers and Trends
The growing demand for improved healthcare services and rising disposable income are creating a scope for the development of advanced diagnostic and treatment techniques. Early diagnostic techniques, during genetic IVF techniques and other artificial insemination procedures, have gained prominence in the healthcare sector because of the rising need to prevent physical disabilities and health conditions in new-borns. Preimplantation diagnostic tests can determine genetic disorders, such as cystic fibrosis, congenital hearing loss, and thalassemia, by diagnosing genetic variations at the embryonic stage. Moreover, governments and non-profit organizations are taking initiatives to spread awareness about the benefits of early diagnosis of genetic disorders to promote the well-being of women and children. These factors are fueling the preimplantation genetic diagnosis market growth over the forecast period.
- A non-invasive biopsy helps in identifying aneuploidy using PGD, which is a proven method to overcome ethical concerns related to invasive embryo analysis and avoid the impact of invasive biopsy procedures on embryo development.
- Non-invasive biopsy procedures rely on collecting embryonic DNA samples from the medium drop fluid that cultures the embryos or sourced from the blastocoel cavity.
- Biopsy procedures offer several benefits over conventional biopsy procedures and avoid risks associated with the removal of cells from embryos.
- The increasing demand for non-invasive biopsy methods will gain traction over the forecast period as it is one of the key preimplantation genetic diagnosis market trends.
- During 2019-2023, the market will grow at a CAGR of over 10%.
Request for a FREE sample now!
Preimplantation Genetic Diagnosis Market: Key Highlights of the Report for the Forecast Period 2019-2023
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the preimplantation genetic diagnosis market growth during the next five years
- Precise estimation of the global preimplantation genetic diagnosis market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the preimplantation genetic diagnosis industry across Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of preimplantation genetic diagnosis vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch